RLYB Stock Recent News

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced its participation in the following upcoming investor conferences: 2024 Wells Fargo Healthcare Conference in Everett, MA on Thursday, September 5, 2024. Stephen Uden, M.D., Chief Executive Officer, will participate in a fireside chat at 3:45 p.m. ET. H.C. Wainwright.

DULUTH, Ga.--(BUSINESS WIRE)--National Vision, Inc., one of the largest optical retail companies in the U.S., released its 2023 Sustainability Report, “A World Worth Seeing.” The report reflects continued progress across its Social, Employees, Environment and Governance (SEE+G) framework. “In 2023, National Vision helped nearly 10 million people see better and live better. Our success as a business is deeply intertwined with our commitment to improving lives through accessible and affordable ey.

Rallybio (RLYB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are you looking for stocks to buy with low price tags?

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported topline results from an epidemiological analysis of large genomic datasets evaluating the frequency of fetal and neonatal alloimmune thrombocytopenia (FNAIT) risk in diverse ancestries. Data from this analysis confirmed Caucasian populations as having the greatest p.

RallyBio (RLYB) gains 83% after announcing a collaboration deal with J&J to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of $6.6 million from the latter.

Rallybio announced it is collaborating with Johnson & Johnson (NYSE:JNJ) on the development of therapies aimed at reducing the risk of a rare fetal disease called fetal and neonatal alloimmune thrombocytopenia (FNAIT). Shares of the biotechnology company soared on the announcement, adding 69.3% at $2.76 late morning on Thursday.

Rallybio (NASDAQ: RLYB ) stock is rocketing higher on Thursday after announcing a collaboration with Johnson & Johnson (NYSE: JNJ ). Rallybio is receiving support from Johnson & Johnson for the development of its fetal and neonatal alloimmune thrombocytopenia (FNAIT) therapies.

Rallybio has proof of concept data from two more assets, RLYB211 and RLYB116, in addition to their lead asset RLYB212. RLYB212 demonstrated rapid and complete elimination of transfused platelets in patients, while RLYB116 showed a reduction in Free C5 greater than 99%. The company has a cash balance of $138mn and a cash runway of approximately 6 quarters.

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences: 2023 Wells Fargo Healthcare Conference in Everett, MA on Thursday, September 7, 2023. Stephen Uden, M.D., Chief Executive Officer, and Martin Mackay, Ph.D., Executive Chairm.